GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2007

Novavax Procures New Virus-Like Particle Technology from UMMS

  • Novavax licensed a new virus-like particle (VLP) technology from the University of Massachusetts Medical School (UMMS) in Worcester.

    The technology was developed in the laboratory of Trudy G. Morrison, Ph.D., professor of molecular genetics and microbiology at UMMS. They used paramyxoviruses as a core for building a VLP vaccine. Parts of the virus are used as a backbone for constructing potentially safer and more effective vaccines.

    Under terms of the worldwide, exclusive agreement, Novavax will have the right to use the UMMS technology to develop VLP vaccines for the prevention of any viral diseases in humans. Novavax will make an upfront cash payment, and certain development-based milestones, and royalties on any sales of products developed using the technology.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

New NIH Budget Proposal Leaves Many Confused and Unsettled

Do you think that using the so-called “mandatory budget funds” to pay for the proposed $825 million increase, as well as $1 billion of the NIH’s existing budget is a good idea?

More »